Certara, Inc. (CERT) Q2 2026 Earnings Call Transcript
Certara, Inc. (CERT) Q2 2026 Earnings Call Transcript
Seeking Alpha8/4/2026Neutral
CERT
Certara IncNASDAQHEALTHCAREHEALTH INFORMATION SERVICES
Key Statistics
Market Cap
$1.22B
P/E Ratio
—
EPS
$-0.14
Beta
1.41
52W High
$13.88
52W Low
$4.45
50-Day MA
$6.77
200-Day MA
$7.36
Dividend Yield
—
Profit Margin
-16.20%
Forward P/E
12.67
PEG Ratio
—
About Certara Inc
Certara Inc. provides software products and technology services to clients for biosimulation in drug discovery, preclinical and clinical research, regulatory filings, and market access. The company is headquartered in Princeton, New Jersey.
Fundamentals
| Revenue (TTM) | $421.75M |
| Gross Profit (TTM) | $259.83M |
| EBITDA | $94.25M |
| Operating Margin | -0.21% |
| Return on Equity | -2.21% |
| Return on Assets | 0.77% |
| Revenue/Share (TTM) | $2.67 |
| Book Value | $6.34 |
| Price-to-Book | 1.26 |
| Price-to-Sales (TTM) | 2.89 |
| EV/Revenue | 3.165 |
| EV/EBITDA | 16.27 |
| Quarterly Earnings Growth (YoY) | -14.10% |
| Quarterly Revenue Growth (YoY) | 1.00% |
| Shares Outstanding | $152.54M |
| Float | $111.95M |
| % Insiders | 2.73% |
| % Institutions | 112.88% |
Historical Volatility
HV 10-Day
35.06%
HV 20-Day
41.17%
HV 30-Day
51.21%
HV 60-Day
65.28%
HV Rank
42.9%
Volatility is currently contracting
Analyst Ratings
Consensus ($8.19 target)
4
Buy8
HoldLatest News
Certara Q2 Earnings Call Highlights
Certara NASDAQ: CERT reported second-quarter 2026 revenue of $93.3 million, up 1% year over year, as software growth offset a decline in services revenue. Management reaffirmed its full-year revenue outlook while outlining further changes to its commercial organization, cost structure and artificial intelligence strategy.
MarketBeat8/4/2026Neutral
Certara, Inc. (CERT) Q2 Earnings and Revenues Lag Estimates
Certara, Inc. (CERT) came out with quarterly earnings of $0.08 per share, missing the Zacks Consensus Estimate of $0.1 per share. This compares to earnings of $0.07 per share a year ago.
Zacks Investment Research8/4/2026Negative
Certara Reports Second Quarter 2026 Financial Results
Appoints Julien Perrier Chief Commercial Officer Completes previously authorized $100 million share repurchase program; Board authorizes additional $50 million under repurchase program Reaffirms 2026 revenue guidance RADNOR, Pa., Aug. 04, 2026 (GLOBE NEWSWIRE) -- Certara, Inc. (Nasdaq: CERT), a global leader in model-informed drug development, today reported its second quarter 2026 financial results.
GlobeNewsWire8/4/2026Neutral
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Certara, Inc. - CERT
NEW YORK, July 23, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Certara, Inc. ("Certara" or the "Company") (NASDAQ: CERT). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext.
PRNewsWire7/23/2026Neutral
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Certara, Inc. - CERT
NEW YORK, July 21, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Certara, Inc. (“Certara” or the “Company”) (NASDAQ: CERT). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.
GlobeNewsWire7/21/2026Neutral
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Certara, Inc. - CERT
NEW YORK, July 16, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Certara, Inc. ("Certara" or the "Company") (NASDAQ: CERT). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext.
PRNewsWire7/16/2026Neutral
Certara to Report Second Quarter 2026 Financial Results on August 4th, 2026
RADNOR, Pa., July 15, 2026 (GLOBE NEWSWIRE) -- Certara, Inc. (Nasdaq: CERT), a global leader in model-informed drug development, today announced that it will release financial results for the second quarter of 2026 before market open on Tuesday, August 4th, 2026. Company management will host a conference call to discuss financial results at 8:30AM ET.
GlobeNewsWire7/15/2026Neutral
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Certara, Inc. - CERT
NEW YORK, July 9, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Certara, Inc. ("Certara" or the "Company") (NASDAQ: CERT). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext.
PRNewsWire7/9/2026Neutral
Certara Accelerates Drug Discovery and Development with NVIDIA BioNeMo Agent Toolkit
RADNOR, Pa., July 07, 2026 (GLOBE NEWSWIRE) -- Certara, Inc. (Nasdaq: CERT), a global leader in model-informed drug development, is partnering with NVIDIA to advance Certara's open integrated AI platform, unifying its scientific software, regulatory expertise, and proprietary datasets with AI-first, agentic frameworks.
GlobeNewsWire7/7/2026Neutral
Turn research into an automated options-selling system
Tiblio connects your broker and runs your put-and-call-writing strategy for you — on CERT and any ticker you trade — then tracks every position and per-strategy win rate.
More HEALTHCARE Stocks
Data last updated: 8/18/2026